NOVEL USE OF IL-1BETA COMPOUNDS

摘要

This application relates to a use of IL-lß ;-ligand/IL-l receptor disrupting compounds (herein referred to as "IL-lbeta Compounds") ; such as small molecular compounds disrupting IL-lß; ligand - IL-I receptor interaction, IL-lß; antibodies or IL-I receptor antibodies, e.g. IL-lß; binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-lß; binding compounds or IL-I receptor binding compounds, and/or RNA compounds decreasing either IL-lß; ligands or IL-I receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans .